Abstract PS4:78 Figure 1 Pregnancy outcome (a) and Kaplan-Meier plot (b) with TTP as dependent variable and achieved pregnancy as event, comparing woman with SLE or RA

Objectives To examine possible differences in the ability to get pregnant and time to pregnancy (TTP) in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Methods Data from RevNatus, a Norwegian nationwide observational register of women with rheumatic diseases planning pregnancy was used. We compared the number of women with SLE and RA achieving pregnancy, TTP and pregnancy outcome (live birth or pregnancy loss). Fifty-three women with SLE and 180 women with RA with a pregnancy wish had follow-up until pregnancy and known pregnancy outcome or at least one year if not achieving pregnancy. With cox regression we adjusted for maternal age, parity and use of disease-modifying antirheumatic drugs (DMARDs).

Results The two groups were similar concerning maternal age, parity, smoking, BMI, educational level, prior pregnancy loss and prior preeclampsia and/or preterm birth. Women with SLE had longer disease duration ($p=0.001$), more often active disease ($p=0.002$) and more often used a DMARD ($p<0.001$). Live birth occurred in 38 (71.7%) women with SLE and 104 (57.5%) women with RA, while pregnancy loss was experienced in 9 (17.0%) and 26 (14.4%), respectively. Six (11.3%) SLE-women and 50 (27.8%) RA-women did not achieve pregnancy during follow-up (Figure 1a). Women with SLE had almost doubled pregnancy rate compared to women with RA (pregnancy ratio 1.91, CI 1.27 to 2.88, $p=0.002$), and when succeeding they also had a substantially shorter mean TTP (3.9 vs 6.2 months, $p=0.017$) (Figure 1b). Sixty-five (65/180, 36.1%) RA-women and eight (8/53, 15.1%) SLE-women had a TTP (or censoring) exceeding one year ($p=0.006$), indicating subfertility.

Conclusions Women with SLE more often achieve pregnancy and have shorter time to pregnancy compared to women with RA.

PS4:79 LONG-TERM FOLLOW-UP OF 320 CHILDREN BORN TO MOTHERS WITH SYSTEMIC AUTOIMMUNE DISEASES: A MULTICENTRE SURVEY FROM 24 RHEUMATOLOGY CENTRES IN ITALY

¹MG Lazzaroni, ¹C Nalli, ¹L Andreoli, ¹C Carini, ¹F Dall'Ara, ²M Rodrigues, ³E Bartoloni Bocci, ³R Gerli, ⁴CB Chighizola, ⁴M Gerosa, ⁴PL Meroni, ⁴L Sinigaglia, ⁵P Conigliaro, ⁵R Perricone, ⁶A Corrado, ⁶F Cantatore, ⁷S D'Angelo, ⁸M Favaro, ⁸M Larosa, ⁸A Doria, ⁸A Ruffatti, ⁹E Generali, ⁹C Selmi, ¹⁰M Meroni, ¹⁰M Cutolo, ¹¹M Padovan, ¹¹M Govoni, ¹²G Pazzola, ¹²C Salvarani, ¹³S Peccatori, ¹⁴I Prevete, ¹⁴G Minisola, ¹⁴GD Sebastiani, ¹⁵A Brucato, ¹⁵V Ramoni, ¹⁶R Caporali, ¹⁶C Montecucco, ¹⁷C Tani, ¹⁷V Signorini, ¹⁷M Mosca, ¹⁸M Trevisani, ¹⁸N Malavolta, ¹⁹M Vadacca, ¹⁹A Afeltra, ²⁰E Vivaldelli, ²⁰A Maier, ²¹E Visalli, ²¹R Foti, ²²L Zuliani, ²²A Gabrielli, ²³C Campochiaro, ²³E Baldissera, ²³MG Sabbadini, ²⁴N Romeo, ¹A Tincani. ¹University and Spedali Civili di Brescia, Italy; ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ³Azienda Ospedaliera di Perugia, Italy; ⁴Istituto Ortopedico Gaetano Pini, Milano, Italy; ⁵Policlinico Tor Vergata, Roma, Italy; ⁶Ospedali Riuniti di Foggia, Foggia, Italy; ⁷Ospedale San Carlo, Potenza, Italy; ⁸University and Azienda Ospedaliera di Padova, Italy; ⁹Humanitas, Milano, Italy; ¹⁰University of Genova, IRCCS San Martino, Genova, Italy; ¹¹University and Azienda Ospedaliera di Ferrara, Italy; ¹²Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio-Emilia, Italy; ¹³Azienda Provinciale Servizi Sanitari, Trento, Italy; ¹⁴A.O. San Camillo, Roma, Italy; ¹⁵Ospedale Papa Giovanni XXXIII, Bergamo, Italy; ¹⁶University and Policlinico San Matteo di Pavia, Italy; ¹⁷University of Pisa, Italy; ¹⁸Policlinico S.Orsola-Malpighi, Bologna, Italy; ¹⁹University Campus Biomedico, Roma, Italy; ²⁰Ospedale di Bolzano, Italy; ²¹Policlinico Vittorio Emanuele-Ferraro-Bambino Gesù, Catania, Italy; ²²Ospedali Riuniti di Ancona, Italy; ²³Ospedale San Raffaele, Milano, Italy; ²⁴Ospedale S. Croce e Carle, Cuneo, Italy

10.1136/lupus-2018-abstract.124

Background Rheumatic Diseases (RD) frequently affect women during reproductive age, therefore counselling on family planning is crucial for their quality of life. Children's outcome is a major topic, but no large studies are available. This study aimed at assessing the long-term health conditions of children born to women with RD.

Methods 24 Italian Rheumatology Centres distributed the questionnaire (65 multiple-choice and 12 open-answer

Abstract PS4:79 Table 1 Autoimmune/inflammatory diseases and neurophychiatric disorders in 320 children, distributed according to maternal diagnosis and timing of pregnancy. CA: chronic arthritis; CTD: connective tissue diseases; SGA: small for Gestational Age. LD: learning disabilities (LD)

	Children born to women with CA (n=113)	Children born to women with CTDs (n=207)
LEARNING DISABILITIES AND NEURODEVELOPMENTAL DISORDERS n=11/320 (3.4%)		
Born BEFORE maternal diagnosis	1/84 (1.2%) 1 "slow learner" (a SGA female)	5/144 (3.5%) 3 LD 1 Attention Deficit Hyperactivity Disorder 1 Autism Spectrum Disorder
Born AFTER maternal diagnosis	0/29 (0%)	5/63 (7.9%) 3 LD 1 Attention Deficit Hyperactivity Disorder 1 Attention Deficit Hyperactivity Disorder + LD
AUTOIMMUNE/INFLAMMATORY DISEASES n=12/320 (3.7%)		
Born BEFORE maternal diagnosis	3/84 (3.6%) 1 Juvenile Rheumatoid Arthritis 1 Diabetes Mellitus type 1 1 Coeliac Disease	4/144 (2.8%) 1 Chronic Autoimmune Thyroiditis 3 Coeliac Disease
Born AFTER maternal diagnosis	1/29 (3.4%) 1 Coeliac Disease	4/63 (6.3%) 1 Fever of Unknown Origin 3 Coeliac Disease

questions) to consecutive patients (aged 18–55) during September 2015. Data were analysed dividing children upon maternal diagnosis: Chronic Arthritis (CA) and Connective Tissue Diseases (CTD).

Results Data were collected for 320 children born to 184 mothers (63 CA and 121 CTD). At the time of interview, children had a mean age of 17.1 ± 9.6 years. Pre-term delivery (<37 w) was observed in 72 cases (22.5%), including 13 (4%) cases born <34 w.

The occurrence of an autoimmune/inflammatory disease (AIID) and/or neurodevelopmental disorders (ND)/learning disabilities (LD) is reported in table 1.

Twelve children (3.7%) were diagnosed with an AIID, mostly coeliac disease (8/12, 67%). Eleven children (3.4%) were diagnosed as having a ND and/or LD by a Paediatric Neuropsychiatrist. Data of in utero exposure to maternal auto-antibodies and/or anti-rheumatic drugs were retrieved for 280 children (87.5%) and a comparison was performed between affected (n=11) and not-affected children (n=258). No association was found with ND/LD and in utero exposure to auto-antibodies (ANA, anti-Ro, anti-dsDNA, aPL) or drugs (HCQ, AZA or steroids), neither with sex, preterm birth, birth weight or maternal diagnosis.

Conclusions The long-term follow-up of children born to mothers with RD did not raise particular concerns in terms of

relevant health problems. In particular, each AIID did not display a significantly increased frequency as compared to the literature. Children with ND/LD had a tendency to cluster in the group of mothers with CTD, especially after maternal diagnosis, with a higher frequency as compared to GPP (7.9% vs 3%).

Our data suggest that the development of ND/LD in children of patients with RD cannot be linked exclusively to maternal disease. The results of this study can be reassuring for patients with RD about problems in the offspring possibly related to their disease.

PS4:80 HYDROXYCHLOROQUINE IN LUPUS PREGNANCY: A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA

¹A Eudy, ²M Petri, ³R Fischer-Betz, ⁴A Mokbel, ⁵C Nalli, ⁵L Andreoli, ⁵A Tincani, ⁶Y Molad, ⁷D Gladman, ⁸M Urowitz. ¹Duke University Medical Centre – Department of Medicine, Durham, USA; ²Johns Hopkins University School of Medicine – Department of Medicine, Baltimore, USA; ³University Hospital Düsseldorf – Department of Rheumatology, Düsseldorf, Germany; ⁴Cairo University Hospital – Department of Rheumatology and Rehabilitation, Cairo, Egypt; ⁵Ospedali Civili and University of Brescia – Rheumatology and Clinical Immunology, Brescia, Italy; ⁶Tel Aviv University – Rheumatology Unit, Tel Aviv, Israel; ⁷University of Toronto – Rheumatology, Toronto, Canada; ⁸University of Toronto – Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, Canada

10.1136/lupus-2018-abstract.125